Clinical Trial: Early Use of Realgar-Indigo Naturalis Formula (RIF) Combined With All-trans Retinoic Acid (ATRA) for Treating Acute Promyelocytic Leukemia (APL).

U.S., April 1 -- ClinicalTrials.gov registry received information related to the study (NCT07503730) titled 'Early Use of Realgar-Indigo Naturalis Formula (RIF) Combined With All-trans Retinoic Acid (ATRA) for Treating Acute Promyelocytic Leukemia (APL).' on Dec. 24, 2025.

Brief Summary: Study Title:

Multicenter, Randomized Controlled Clinical Study on Early Application of Realgar-Indigo Naturalis Formula (RIF) for Treatment of Acute Promyelocytic Leukemia (APL)

Sponsor:

Xi'an Jiaotong University First Affiliated Hospital

Principal Investigator:

Wang Huaiyu

Study Description:

This multicenter, randomized controlled trial evaluates whether early induction treatment with oral Realgar-Indigo Naturalis Formula (RIF) combined with all-tr...